107 related articles for article (PubMed ID: 35344645)
1. Moderate hypofractionated helical tomotherapy for older patients with localized prostate cancer: long-term outcomes of a phase I-II trial.
Cui D; Du L; Yu W; Cai B; Meng L; Yang J; Luo Y; Chen J; Ma L
Radiol Oncol; 2022 Mar; 56(2):216-227. PubMed ID: 35344645
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated Helical Tomotherapy for Older Aged Patients With Prostate Cancer: Preliminary Results of a Phase I-II Trial.
Liu HX; Du L; Yu W; Cai BN; Xu SP; Xie CB; Ma L
Technol Cancer Res Treat; 2016 Aug; 15(4):546-54. PubMed ID: 26152749
[TBL] [Abstract][Full Text] [Related]
3. Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study.
Cuccia F; Mazzola R; Arcangeli S; Mortellaro G; Figlia V; Caminiti G; Di Paola G; Spera A; Iacoviello G; Alongi F; Lo Casto A; Magrini SM; Ferrera G
Tumori; 2019 Dec; 105(6):516-523. PubMed ID: 31432765
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.
Lopez Guerra JL; Isa N; Matute R; Russo M; Puebla F; Kim MM; Sanchez-Reyes A; Beltran C; Jaen J; Bourgier C; Marsiglia H
Clin Transl Oncol; 2013 Apr; 15(4):271-7. PubMed ID: 22855189
[TBL] [Abstract][Full Text] [Related]
5. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
[TBL] [Abstract][Full Text] [Related]
6. Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis.
Cuccia F; Mortellaro G; Trapani G; Valenti V; Ognibene L; De Gregorio G; Quartuccio E; Luca N; Tripoli A; Serretta V; Lo Casto A; Ferrera G
Radiol Med; 2020 Feb; 125(2):220-227. PubMed ID: 31641931
[TBL] [Abstract][Full Text] [Related]
7. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer.
Wang MH; Vos LJ; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Ghosh S; Field C; Fallone BG; Murtha AD
Pract Radiat Oncol; 2021; 11(5):384-393. PubMed ID: 33705985
[TBL] [Abstract][Full Text] [Related]
9. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
10. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
11. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
12. Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes.
Ferrera G; D'Alessandro S; Cuccia F; Serretta V; Trapani G; Savoca G; Mortellaro G; Lo Casto A
J Cancer Res Clin Oncol; 2022 Jan; 148(1):89-95. PubMed ID: 34595542
[TBL] [Abstract][Full Text] [Related]
13. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
15. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
17. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
19. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
20. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H
Anticancer Res; 2017 Oct; 37(10):5829-5835. PubMed ID: 28982908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
